BioPartnering North America

BioPartnering North America

January 15, 2008 12:22 ET

International Life Science Community to Converge in Vancouver, Canada for the 6th Annual BioPartnering North America Conference

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 15, 2008) - In less than a month, leading international biotechnology and pharmaceutical companies will converge at the Westin Bayshore Resort in Vancouver, Canada for the 6th Annual BioPartnering North America (BPN) conference. Sponsored by LifeSciences British Columbia, BIOTECanada, and BioAlberta, BPN takes place on February 3-5, 2008. Meeting arrangements on have begun and agendas are filling fast.

Register now at: in order to take full benefit of all the partnering opportunities provided.

The conference remains as popular as ever with over 600 international participants registered so far. Attendees include market leaders from the biotechnology, pharmaceutical and financial industries. BPN offers a perfect environment to facilitate an excellent partnering experience, including views and perspectives from key players in the industry.

Highlights from the conference include the workshop Driving the Deal: Positioning for the Optimal Partnership or Being Acquired, addressing the questions of how to optimize the chances of a deal, ensuring approval and whether businesses are truly bought not sold. There will also be pharmaceutical presentations given by AstraZeneca, Merck & Co., Novartis, Pfizer, Proctor & Gamble, Roche, Wyeth and Angiotech Pharmaceuticals.

Other highlights of the conference program include:

- 56 Open House presentations - interactive presentations in specially constructed booths to allow informal discussion

- 22 Emerging Company presentations - young companies in 14-minute podium presentations

- 5 BioPartnering Leadership Sessions - senior executives from the financial, pharma, and biotech industries address cutting-edge themes of the day in panel discussions

- 8 Sponsor Workshops - leading service providers offer 1-hour workshops on unique topics in an interactive environment

- Networking opportunities - including a special opening reception on Sunday, February 3 and a reception and dinner on Monday, February 4

- - BPN's state-of-the-art partnering system allowing delegates to organize their time more efficiently and in advance of the event.

The Conference program details are now online, please go to:

Media registration is also available and is complimentary for accredited members of the news media. To register for BPN or for further information please contact Amber Bielecka or Mark Swallow at at Citigate Dewe Rogerson for further details.

Conference Sponsors

Platinum Sponsors

Angiotech, AstraZeneca, and Province of British Columbia

Gold Sponsors

Burrill & Company, Cooley Godward Kronish LLP, Ferghana Partners Group, Morrison & Foerster, Wilson Sonsini Goodrich & Rosati, and Wyeth

Silver Sponsors

Bristol-Myers Squibb Company, Crucell, Farris, Vaughan, Wills & Murphy LLP, Italian Trade Commission, Merck & Co., Inc., Novartis, Pfizer Inc., PricewaterhouseCoopers, Procter & Gamble Pharmaceuticals, Roche, Seed Intellectual Property Law Group PLLC, and UK Trade & Investment.

Conference Sponsors

Anapharm, BC Innovation Council, Genome British Columbia, Marsh Canada Ltd., and VWR International.

Conference & Media Supporters

BIA, Bio Business, BioCentury, Biotechnology Focus, BioWorld Today, Citigate Dewe Rogerson, Contact Canada, European Biopharmaceutical Review, MarketWire, Nature Publishing Group, and Washington Biotechnology & Biomedical Association.

2008 Presenting Companies

Achaogen, Inc., Akebia Therapeutics, Alfama Inc., Alphora Research Inc., Ambit Biosciences, Apthera, Inc., Aquinox Pharmaceuticals Inc., Aska Research, Benitec, Biolex Therapeutics, BioMarck Pharmaceuticals, Ltd., Burnham Institute for Medical Research, Calibrant Biosystems, Inc., Ceapro Inc., Cequent Pharmaceuticals, CIRION BioPharma Research Inc., ConjuChem Inc., Cook Pharmica LLC, Critical Outcome Technologies, Crucell BV, Curis, Inc., Cytochroma Inc., Cytokinetics, Inc., deCODE Genetics, Inc., Eurand International S.p.A., Evotec (UK) Limited, Fresenius AG, Ichor Medical Systems, Inc., ImmunoVaccine Technologies Inc., Inimex Pharmaceuticals, Inc., InNexus Biotechnology Inc., Inovio Biomedical Corp., IRX Therapeutics, Inc., Kane Biotech Inc., Laureate Pharma, Inc., MDS Pharma Services, Nektar Therapeutics, Nerites Corporation, NeuroProtect, Inc., NPIL Pharma Torcan, Oculus Innovative Sciences, Inc., Office of Biomedical Advanced Research and Development Authority (BARDA), Oscient Pharmaceuticals Corp., OxThera, Patheon Inc., Perceptronix Medical, Inc., PGxHealth Inc., Pharmaceutical Profiles Ltd., Pharmatek Laboratories, Inc., Pharmexa-Epimmune, Plexera Corporation, Presidio Pharmaceuticals, ProCell Therapeutics, Inc./Chonnam National, ProtAffin Biotechnologie AG, Quest PharmaTech Inc., Regeron, Inc., Ribomed Biotechnologies, Inc., Sapphire Therapeutics, Scimega Research Inc., Sensific Technologies Inc., Sidec Technologies AB, Silence Therapeutics AG, Sloning BioTechnology, Solmap Pharmaceuticals, Stelic Institute & Co., Stem Cell Therapeutics Corp., SuperGen Inc., Syngene International Ltd., Thallion Pharmaceuticals, The Hungarian Investment and Trade Development Agency (ITD Hungary), The Vaccines Company, Tripos Inc., TriStar Technology Group, LLC., Urigen Pharmaceuticals, Inc., Urodynamix Technologies Ltd., VentiRx, VM Discovery, Inc., Vyteris, Welichem Biotech Inc., XOMA Ltd., Xytis, Inc., YM BioSciences Inc., Zosano Pharma, Inc.

Contact Information